ChemoCentryx (CCXI)

[jgrabar]

Current ChemoCentryx, Inc. shareholders who have held shares of the Company’s stock since at least November 26, 2019, can seek corporate reforms, the return of funds back to company coffers and potentially a court approved incentive award if appropriate.

The underlying class action complaint alleges that the defendants misrepresented and/or failed to disclose to investors that: (1) the study design of the Phase III ADVOCATE drug trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of AAV; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx’s NDA for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, the defendants’ public statements were materially false and misleading at all relevant times.

If you would like to learn more about this matter at no cost to you, please fill out the form provided or contact us at [e-mail] or call 267-507-6085.

https://grabarlaw.com/the-latest/chemocntryx-investigation/